Page last updated: 2024-08-21

pyrazines and ridaforolimus

pyrazines has been researched along with ridaforolimus in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cavalli, F; Johnston, PB; Witzig, TE; Yuan, R	1
Amin, HM; Benjamin, RS; Buford, AS; Daw, NC; Fokt, I; Lamhamedi-Cherradi, SE; Lazar, AJ; Ludwig, JA; Maywald, RL; Menegaz, BA; Mikos, AG; Naing, A; Priebe, W; Ramamoorthy, V; Ratan, R; Rohren, EM; Skora, S; Subbiah, V; Vishwamitra, D; Wang, J; Wang, Y	1

Reviews

1 review(s) available for pyrazines and ridaforolimus

Article	Year
Targeted therapy in lymphoma. Journal of hematology & oncology, 2010, Nov-23, Volume: 3 Topics: Boronic Acids; Bortezomib; Everolimus; Humans; Lymphoma; Molecular Targeted Therapy; Pyrazines; Signal Transduction; Sirolimus; Survival Analysis	2010

Other Studies

1 other study(ies) available for pyrazines and ridaforolimus

Article	Year
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:12 Topics: Adenosine Triphosphatases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cation Transport Proteins; Cell Line, Tumor; Copper-Transporting ATPases; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Insulin Receptor Substrate Proteins; Male; Mice; Mice, SCID; Neoplasm Transplantation; Nucleocytoplasmic Transport Proteins; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Array Analysis; Pyrazines; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptors, Somatomedin; Sarcoma, Ewing; Sirolimus; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Up-Regulation	2016

Article

Year

IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.

Journal of the National Cancer Institute, 2016, Volume: 108, Issue:12

Topics: Adenosine Triphosphatases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cation Transport Proteins; Cell Line, Tumor; Copper-Transporting ATPases; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Insulin Receptor Substrate Proteins; Male; Mice; Mice, SCID; Neoplasm Transplantation; Nucleocytoplasmic Transport Proteins; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Array Analysis; Pyrazines; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptors, Somatomedin; Sarcoma, Ewing; Sirolimus; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Up-Regulation

2016